First Wave Biopharma Stock Price To Book

FWBIDelisted Stock  USD 0.61  0.03  4.69%   
First Wave BioPharma fundamentals help investors to digest information that contributes to First Wave's financial success or failures. It also enables traders to predict the movement of First Stock. The fundamental analysis module provides a way to measure First Wave's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to First Wave stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

First Wave BioPharma Company Price To Book Analysis

First Wave's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

 = 

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current First Wave Price To Book

    
  1.87 X  
Most of First Wave's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, First Wave BioPharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.
Competition

Based on the latest financial disclosure, First Wave BioPharma has a Price To Book of 1.8662 times. This is 92.73% lower than that of the Biotechnology sector and 69.1% lower than that of the Health Care industry. The price to book for all United States stocks is 80.38% higher than that of the company.

First Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses First Wave's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of First Wave could also be used in its relative valuation, which is a method of valuing First Wave by comparing valuation metrics of similar companies.
First Wave is currently under evaluation in price to book category among its peers.

First Fundamentals

About First Wave Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze First Wave BioPharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of First Wave using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of First Wave BioPharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Currently Active Assets on Macroaxis

Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.
You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Other Consideration for investing in First Stock

If you are still planning to invest in First Wave BioPharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the First Wave's history and understand the potential risks before investing.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Investing Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Idea Optimizer
Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments